Dependence receptors: new targets for cancer therapy

Abstract Dependence receptors are known to promote survival and positive signaling such as proliferation, migration, and differentiation when activated, but to actively trigger apoptosis when unbound to their ligand. Their abnormal regulation was shown to be an important feature of tumorigenesis, al...

Full description

Saved in:
Bibliographic Details
Main Authors: Morgan Brisset, Mélodie Grandin, Agnès Bernet, Patrick Mehlen, Frédéric Hollande
Format: Article
Language:English
Published: Springer Nature 2021-09-01
Series:EMBO Molecular Medicine
Subjects:
Online Access:https://doi.org/10.15252/emmm.202114495
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343562507878400
author Morgan Brisset
Mélodie Grandin
Agnès Bernet
Patrick Mehlen
Frédéric Hollande
author_facet Morgan Brisset
Mélodie Grandin
Agnès Bernet
Patrick Mehlen
Frédéric Hollande
author_sort Morgan Brisset
collection DOAJ
description Abstract Dependence receptors are known to promote survival and positive signaling such as proliferation, migration, and differentiation when activated, but to actively trigger apoptosis when unbound to their ligand. Their abnormal regulation was shown to be an important feature of tumorigenesis, allowing cancer cells to escape apoptosis triggered by these receptors while promoting in parallel major aspects of tumorigenesis such as proliferation, angiogenesis, invasiveness, and chemoresistance. This involvement in multiple cancer hallmarks has raised interest in dependence receptors as targets for cancer therapy. Although additional studies remain necessary to fully understand the complexity of signaling pathways activated by these receptors and to target them efficiently, it is now clear that dependence receptors represent very exciting targets for future cancer treatment. This manuscript reviews current knowledge on the contribution of dependence receptors to cancer and highlights the potential for therapies that activate pro‐apoptotic functions of these proteins.
format Article
id doaj-art-0c4f0d08899a4d80b0e26d0f7659852a
institution Kabale University
issn 1757-4676
1757-4684
language English
publishDate 2021-09-01
publisher Springer Nature
record_format Article
series EMBO Molecular Medicine
spelling doaj-art-0c4f0d08899a4d80b0e26d0f7659852a2025-08-20T03:42:56ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842021-09-01131111410.15252/emmm.202114495Dependence receptors: new targets for cancer therapyMorgan Brisset0Mélodie Grandin1Agnès Bernet2Patrick Mehlen3Frédéric Hollande4Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of MelbourneDepartment of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of MelbourneApoptosis, Cancer and Development Laboratory, Centre de Recherche en Cancérologie de Lyon, INSERM U1052‐CNRS UMR5286, Centre Léon Bérard, Université de LyonApoptosis, Cancer and Development Laboratory, Centre de Recherche en Cancérologie de Lyon, INSERM U1052‐CNRS UMR5286, Centre Léon Bérard, Université de LyonDepartment of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of MelbourneAbstract Dependence receptors are known to promote survival and positive signaling such as proliferation, migration, and differentiation when activated, but to actively trigger apoptosis when unbound to their ligand. Their abnormal regulation was shown to be an important feature of tumorigenesis, allowing cancer cells to escape apoptosis triggered by these receptors while promoting in parallel major aspects of tumorigenesis such as proliferation, angiogenesis, invasiveness, and chemoresistance. This involvement in multiple cancer hallmarks has raised interest in dependence receptors as targets for cancer therapy. Although additional studies remain necessary to fully understand the complexity of signaling pathways activated by these receptors and to target them efficiently, it is now clear that dependence receptors represent very exciting targets for future cancer treatment. This manuscript reviews current knowledge on the contribution of dependence receptors to cancer and highlights the potential for therapies that activate pro‐apoptotic functions of these proteins.https://doi.org/10.15252/emmm.202114495apoptosiscancer hallmarkstreatment resistancetumor progression
spellingShingle Morgan Brisset
Mélodie Grandin
Agnès Bernet
Patrick Mehlen
Frédéric Hollande
Dependence receptors: new targets for cancer therapy
EMBO Molecular Medicine
apoptosis
cancer hallmarks
treatment resistance
tumor progression
title Dependence receptors: new targets for cancer therapy
title_full Dependence receptors: new targets for cancer therapy
title_fullStr Dependence receptors: new targets for cancer therapy
title_full_unstemmed Dependence receptors: new targets for cancer therapy
title_short Dependence receptors: new targets for cancer therapy
title_sort dependence receptors new targets for cancer therapy
topic apoptosis
cancer hallmarks
treatment resistance
tumor progression
url https://doi.org/10.15252/emmm.202114495
work_keys_str_mv AT morganbrisset dependencereceptorsnewtargetsforcancertherapy
AT melodiegrandin dependencereceptorsnewtargetsforcancertherapy
AT agnesbernet dependencereceptorsnewtargetsforcancertherapy
AT patrickmehlen dependencereceptorsnewtargetsforcancertherapy
AT frederichollande dependencereceptorsnewtargetsforcancertherapy